Tokyo Tape
Sign in
← Nihon Chouzai

Half-year report · Q2

3341.TEDINET S100URMJ
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥175.6bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥340.3bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥166.3bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥423m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.4bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥772m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.4bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.4bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥762m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥43m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥43m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥204.1bnat 2024-09-30Cons.Assets
Total assets¥195.1bnat 2024-03-31Cons.Assets
Total assets¥193.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥146.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥136.7bnat 2024-03-31Cons.Liabilities
Net assets / equity¥57.9bnat 2024-09-30Cons.Net assets
Net assets / equity¥58.4bnat 2024-03-31Cons.Net assets
Net assets / equity¥57.9bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥26.4bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥26.0bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥26.4bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.0bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥22.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.8bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥20.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥6.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥8.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥4.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-1.442024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.352023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥58.442023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio28.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.9%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio29.9%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥6.6bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥6.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥156.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥156.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.5bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥122m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥766m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥19.6bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥6.5bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥652m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥182.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥175.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥6.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥4.6bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥3.5bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥14m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥698m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥167m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥173.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥166.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥6.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 520
ItemContextValueUnit
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration26000000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration3000000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-1351000000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-1560000000JPY
Proceeds from sales of investment securities inv cfPrior1YTDDuration－JPY
Proceeds from sales of investment securities inv cfCurrentYTDDuration18000000JPY
Purchase of long term prepaid expenses inv cfPrior1YTDDuration-32000000JPY
Purchase of long term prepaid expenses inv cfCurrentYTDDuration-37000000JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfPrior1YTDDuration-273000000JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfCurrentYTDDuration-436000000JPY
Payments for transfer of business2 inv cfPrior1YTDDuration-275000000JPY
Payments for transfer of business2 inv cfCurrentYTDDuration－JPY
Payments of loans receivable inv cfPrior1YTDDuration－JPY
Payments of loans receivable inv cfCurrentYTDDuration-49000000JPY
Collection of loans receivable inv cfPrior1YTDDuration32000000JPY
Collection of loans receivable inv cfCurrentYTDDuration170000000JPY
Payments for lease and guarantee deposits inv cfPrior1YTDDuration-2658000000JPY
Payments for lease and guarantee deposits inv cfCurrentYTDDuration-395000000JPY
Proceeds from collection of lease and guarantee deposits inv cfPrior1YTDDuration59000000JPY
Proceeds from collection of lease and guarantee deposits inv cfCurrentYTDDuration112000000JPY
Other net inv cfPrior1YTDDuration-20000000JPY
Other net inv cfCurrentYTDDuration23000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-8019000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-5956000000JPY
Net increase decrease in short term loans payable fin cfPrior1YTDDuration-2000000000JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration4850000000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration5500000000JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration9450000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-8477000000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-8987000000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-0JPY
Purchase of treasury stock fin cfCurrentYTDDuration-69000000JPY
Cash dividends paid fin cfPrior1YTDDuration-374000000JPY
Cash dividends paid fin cfCurrentYTDDuration-374000000JPY
Other net fin cfPrior1YTDDuration-72000000JPY
Other net fin cfCurrentYTDDuration-86000000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-5425000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration4780000000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-1544000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration389000000JPY
Cash and cash equivalentsPrior2YearInstant23770000000JPY
Cash and cash equivalentsPrior1YearInstant26034000000JPY
Cash and cash equivalentsPrior1QuarterInstant22226000000JPY
Cash and cash equivalentsCurrentQuarterInstant26424000000JPY
Salaries and allowances sgaPrior1YTDDuration3074000000JPY
Salaries and allowances sgaCurrentYTDDuration3277000000JPY
Directors compensations sgaPrior1YTDDuration239000000JPY
Directors compensations sgaCurrentYTDDuration229000000JPY
Provision for bonuses sgaPrior1YTDDuration856000000JPY
Provision for bonuses sgaCurrentYTDDuration832000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass